Background: In Mexico, it is estimated that the adolescent population represents 29% of the population of childbearing age. The present study aimed to analyze the obstetric results of 3310 adolescent pregnant women attended in a third level hospital. Material and methods: All records of pregnant women aged 19 years or less up to the date of admission were analyzed at the Mónica Pretelini Saenz Maternal Perinatal Hospital during the period from January 2018 to June 2020, with the following variables: age, pregnancy, resolution obstetric, severe preeclampsia, preeclampsia and gestational hypertension. Results: A total of 13874 pregnant women were attended, of which 3310 (24%) patients were adolescents. The overall frequency of obstetric complications was 21%, including obstetric hemorrhage (13%) and hypertensive disorders of pregnancy (8%). Regarding postpartum obstetric hemorrhage events, classified according to the Advanced Trauma Life Support shock scale, they were categorized as Grade 1 – 338 cases, Grade II – 76 cases, Grade III – 11 cases and Grade IV – 1 case. Hypertensive disorders of pregnancy highlight preeclampsia as the most frequent with a total of 97 cases, followed by 89 cases of severe preeclampsia, 58 cases of gestational hypertension, 14 cases of chronic hypertension and 3 cases of chronic hypertension with preeclampsia. Conclusions: The main complications found in the Mexican pregnant adolescent population were obstetric hemorrhage, which was more frequent in the population aged 15 to 19 years, and hypertensive disorders, which occurred more frequently in the population aged 9 to 14 years.

No abstract

Covid-19 was the third leading cause of death in all of 2020, but in December 2020 and the beginning of 2021, the disease suddenly spiked and briefly became the number one cause of death in the United States (u.s.), particularly among those aged 35 years or older even though as of June 30, 2021, about 66% of adults in the u.s. have received at least one Covid-19 vaccine dose. At present, there is no drug to treat Covid-19 that can reduce the morbidity and mortality significantly, which has brought great panic to the society and scientific community. Antiviral agents and immune-modulating treatments are currently being trialed. Searches were conducted in PubMed, ScienceDirect, Google Academic, LitCovid, and MedRxiv for studies published from the beginning of 2000 through April 2021 that tested the clinical uses of pidotimod. Articles were selected prioritizing randomized clinical trials, systematic reviews, and clinical practice guidelines. Research results showed that Immunotherapy proved to be an effective method for fighting against similar viral infections to Covid-19 such as sars-cov, and Middle East respiratory syndrome coronavirus (mers-cov). studies aimed to dilucidated the mechanism of action of pidotimod, as well as randomized clinical trials that evaluate the security and utility of the drug are needed. In this scenario, the administration of Pidotimod could represent a potentially innovative strategy. In conclusion, in patients with Covid-19 without pneumonia, pidotimod could be considered an option, well-tolerated, and associated with a rapid reduction of systemic symptoms of the disease

No abstract